Skip to content
Evofem Biosciences, Inc.
About Us
Mission
Management
Board of Directors
Saundra Pelletier
GILLIAN GREER, CBE, Ph.D.
KIM P. KAMDAR, Ph.D.
Tony O’Brien
Lisa Rarick, MD, FACOG
Colin Rutherford
Our Product
phexxi
®
Pipeline
In Development
Posters & Publications
Investors
Investor Overview
Events & Presentations
Press Releases
Stock Information
Financial Information
SEC Filings
Analyst Coverage
Corporate Governance
Committee Composition
Board of Directors
Charters + Code of Ethics
Investor Resources
Investor Contact
Investor FAQs
Contact
Investor Contact
Media Contact
General Contact
Careers
Timing of On-Study Pregnancies with a Vaginal pH Modulator in the Phase 3 AMPOWER Trial
Post navigation
Previous:
Side Effects by Frequency of Use with EVO100 Vaginal Gel: Results From The Phase 2B/3 AMPREVENCE Trial.
Next:
Incorporating Direct Patient Health Outcomes into Clinical Trials for the Prevention of Urogenital Chlamydia Trachomatis Infection: Analysis of a Novel Endpoint in a Clinical Trial of EVO100 (EVO-003)
Back
to
Top
